Aurora Cannabis Inc.

Canadian Cannabis

Neil Maruoka, MSc, MBA | Analyst | Canaccord Genuity Corp. (Canada) | nmaruoka@canaccordgenuity.com |
Canadian Equity Research 1.416.869.3073
29 June 2017 Matt Bottomley, CPA, CA, CBV | Analyst | Canaccord Genuity Corp. (Canada) | mbottomley@canaccordgenuity.com |
1.416.867.2394
Matthew Reitsma | Associate | Canaccord Genuity Corp. (Canada) | mreitsma@canaccordgenuity.com | 1.416.869.7703
SPECULATIVE BUY
unchanged
PRICE TARGET C$3.25
unchanged Company Update
Price (28-Jun) C$2.16
Ticker ACB-TSXV
Aurora provides positive update
52-Week Range (C$): 0.05 - 3.95 Aurora has provided a positive update on its Canadian operations, highlighting solid
Avg Daily Vol (000s) : 2,873.1
Market Cap (C$M): 805
patient growth and accelerating sales of cannabis oils. The company reported more than
Shares Out., Basic (M) : 360.5 16,000 active registered patients, a 22% increase since the end of Q3 (March 31). With
Shares Out., Basic + Dil. (M) : 381.3 the launch of its cannabis oils products in April 2017, the company announced record
Total Return to Target (%) : 54.0 monthly revenue in May of $2.4 million, a 38% increase over the average monthly sales
Net Debt (Cash) (C$M): (58)
for the third quarter (January through March of this year). Additional updates included
Long-Term Debt (C$M): 103.7
a modest price increase in May, a two-year license renewal for its existing production
FYE Jun 2016A 2017E 2018E 2019E facility, and a vault upgrade. We view the license renewal to be positive validation from
Revenue (C$M) 1 27 192 379 Health Canada of Auroras cultivation practices.
SG&A (C$M) 4.7 14.7 70.4 139.8 Our un-risked analysis for Aurora suggests a valuation in excess of $5.00 per share
R&D (C$M) 0.6 0.2 1.4 2.3 if marijuana is legalized in Canada, supporting our SPECULATIVE BUY rating as the
EBITDA1 (C$M) (6.0) 7.9 80.2 173.2 pathway to the rec market further unfolds this year. We would remain buyers of the stock
EPS2 (C$) (0.04) 0.01 0.15 0.34 ahead of construction milestones for the Aurora Sky facility and significant industry
1Adjusted
catalysts expected in coming months.
2Adj & diluted

3.5
Investment highlights
3
CanvasRx continues to expand its geographic footprint. CanvasRx continues to
expand its presence, growing to 24 cannabis clinics across Canada. We believe that
2.5 CanvasRx is an important driver of the companys patient growth, having facilitated
2
over 6,800 patients registering with Aurora, or ~42% of its patient base.
1.5
Aurora Sky tracking for late-2017 production. Aurora provided another update on its
800,000 square foot Aurora Sky hybrid greenhouse, reporting that one-quarter of its
1 planned footprint has been erected so far. At a total cost of ~$110 million, the facility
0.5 is expected to commence production in late-2017. Full construction is expected to be
complete in 2018, with full production reached the following year.
0
Balance sheet should fund Auroras aggressive growth plans. Aurora ended the most
May-17
Aug-16

Mar-17
Nov-16

Apr-17
Dec-16

Feb-17
Sep-16

Jun-17
Oct-16

Jan-17
Jul-16

recent quarter with pro forma cash and equivalents of $111 million, which we believe
ACB should be more than sufficient to fund the construction of its Aurora Sky cannabis
Source:FactSet
S&P/TSXVentureComposite(rebased)
greenhouse facility and advance its Canadian and international strategies.
Priced as of close of business 28 June 2017 Valuation
We value Aurora using a sum-of-the-parts analysis; the medical cannabis market based
on a DCF model, using a 13.0% WACC and 2.0% terminal growth, and the higher-risk
rec opportunity is valued using a probability-weighted NPV. Based on this analysis, we
are maintaining our target price of $3.25. For Aurora, we note that the entire medical
opportunity represents ~$1.82 per share (providing a stable underpinning to our
valuation), while our risked valuation of the rec market reflects the remaining ~$1.40 per
share in our target price.

Canaccord Genuity is the global capital markets group of Canaccord Genuity Group Inc. (CF : TSX)
The recommendations and opinions expressed in this research report accurately reflect the research analyst's personal, independent and objective views about any and all
the companies and securities that are the subject of this report discussed herein.

For important information, please see the Important Disclosures beginning on page 3 of this document.
 Aurora Cannabis Inc.
Company Update

Figure 1: Summary sheet

Company Description Consolidated Balance Sheet
Aurora is a Licensed Producer (LP) of medical cannabis, having obtained its license to Year end June 30 $000s 2016A 2017E 2018E 2019E
sell marijuana in November 2015. The company currently operates out of a customized Cash 170 88,104 75,041 136,472
55,200 square foot indoor growing facility located in Cremona, Alberta, with the capacity
Current Assets 5,244 104,272 135,585 265,818
to produce ~8,000KG of cannabis per year. Aurora has formalized plans to expand its
production footprint by ten-fold, to ~800,000 square feet that will add an additional Fixed Assets 11,370 36,634 71,177 74,868
~100,000KG of capacity. Total Assets 18,397 142,688 208,544 342,469
Current Liabilities 7,995 8,676 20,313 32,068
Debt 10,487 101,047 101,047 101,047
P&L Forecasts Shareholders Equity 5,962 39,012 93,231 215,401
Year end June 30 $000s 2016A 2017E 2018E 2019E
Kgs of cannabis sold 257 3,254 24,767 45,720 Total Liabilities & S/E 18,397 142,688 208,544 342,469

Ave. Price per gram $ 5.60 $ 7.78 7.57 8.21 Revenue Forecasts

Revenue 1,439 26,956 192,265 379,313

600,000 $8.40
Production Costs 2,241 4,022 40,210 64,008 $8.30
Operating Expenses 6,793 17,533 76,736 148,161 500,000
$8.20
Adj. EBITDA (6,017) 7,933 80,225 173,233 400,000
$8.10

Depreciation/Amortization 593 612 2,707 3,559 $8.00

300,000 $7.90
Interest Expense (Income) 73 2,050 2,050 2,050
$7.80
Income Before Taxes (5,872) 4,482 73,269 165,095 200,000
$7.70
Taxes 0 0 19,050 42,925
$7.60
100,000
Net Income (5,723) 5,166 54,219 122,170 $7.50
Shares o/s (basic) 128,988 323,546 323,546 323,546 0 $7.40
2017 2018 2019 2020
Shares o/s (FD) 128,988 339,636 339,636 339,636
Revenue Revenue per gram
EPS - FD (0.04) 0.01 0.15 0.34

Cash Flow Forecasts Production Forecasts in Kilograms

Year end June 30 $000s 2016A 2017E 2018E 2019E
Net Income (5,723) 5,166 54,219 122,170 60,000
Adj, EBITDA (6,017) 7,933 80,225 173,233
50,000
Change in Working Capital (286) 17,705 36,658 26,976
Cash Taxes - - - 19,050 40,000
Capex 1,885 25,000 37,250 7,250
30,000
Free Cash Flow (7,616) (22,458) 3,178 85,649
20,000
Growth Analysis
Year end June 30 $000s 2016A 2017E 2018E 2019E 10,000
Revenue nmf nmf 613% 97%
0
EBITDA nmf nmf 911% 116%
2017 2018 2019 2020
Net Income nmf -190% 950% 125% Total kgs sold Kgs sold (Medical) Kgs sold (Recreational)

Margin Analysis Valuation Ratios

Year end June 30 $000s 2016A 2017E 2018E 2019E Year end June 30 $000s 2017 2018 2019
Gross Margin nmf 82% 79% 83% Enterprise Value / Revenue 21.6x 3.0x 1.5x

EBITDA nmf 29% 42% 46% Enterprise Value / EBITDA 73.5x 7.3x 3.4x

Net Income nmf 19% 28% 32%

Source: Company Reports, Canaccord Genuity estimates

2
Speculative Buy unchanged Target Price C$3.25 unchanged | 29 June 2017 Canadian Cannabis 2
 Aurora Cannabis Inc.
Company Update

Appendix: Important Disclosures

Analyst Certification
Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the
recommendations and opinions expressed in this research accurately reflect the authoring analysts personal, independent and
objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring
analysts coverage universe and (ii) no part of the authoring analysts compensation was, is, or will be, directly or indirectly, related to the
specific recommendations or views expressed by the authoring analyst in the research.
Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of
Canaccord Genuity Inc. and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications
with a subject company, public appearances and trading securities held by a research analyst account.
Sector Coverage
Individuals identified as Sector Coverage cover a subject companys industry in the identified jurisdiction, but are not authoring
analysts of the report.

Investment Recommendation
Date and time of first dissemination: June 29, 2017, 09:44 ET
Date and time of production: June 29, 2017, 09:44 ET
Target Price / Valuation Methodology:
Aurora Cannabis Inc. - ACB
We value the medical cannabis market based on a DCF model, using a 13.0% WACC and 2.0% terminal growth; the higher-risk rec
opportunity is valued using a probability-weighted NPV. Together, these two analyses yield a target price of C$3.25.
Risks to achieving Target Price / Valuation:
Aurora Cannabis Inc. - ACB
Key risks for Aurora Cannabis include, but are not limited to: continued patient uptake in the medical market; uncertainty pertaining to
the potential recreational market in terms of pricing, distribution and regulation; pressure on margins if/when the industry transitions
to a wholesale model; reliance on Health Canada to continue to renew production/sales licenses; the potential for unfavorable public
opinion if products are not used responsibly; increased competition from other LPs if production capacity continues to expand industry
wide; the reliance on agricultural operations that are subject to external factors (climate, etc); and, execution risk and achieving lower
cost production associated with planned facility expansions.

Distribution of Ratings:
Global Stock Ratings (as of 06/29/17)
Rating Coverage Universe IB Clients
# % %
Buy 580 60.99% 40.17%
Hold 271 28.50% 20.66%
Sell 26 2.73% 15.38%
Speculative Buy 74 7.78% 68.92%
951* 100.0%
*Total includes stocks that are Under Review

Canaccord Genuity Ratings System

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.
HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.
SELL: The stock is expected to generate negative risk-adjusted returns during the next 12 months.
NOT RATED: Canaccord Genuity does not provide research coverage of the relevant issuer.
Risk-adjusted return refers to the expected return in relation to the amount of risk associated with the designated investment or the
relevant issuer.
Risk Qualier
SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the
stock may result in material loss.

Speculative Buy unchanged Target Price C$3.25 unchanged | 29 June 2017 Canadian Cannabis 3
 Aurora Cannabis Inc.
Company Update

12-Month Recommendation History (as of date same as the Global Stock Ratings table)
A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period
may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures-
mar.canaccordgenuity.com/EN/Pages/default.aspx

Required Company-Specific Disclosures (as of date of this publication)

Aurora Cannabis Inc. currently is, or in the past 12 months was, a client of Canaccord Genuity or its affiliated companies. During this
period, Canaccord Genuity or its affiliated companies provided investment banking services to Aurora Cannabis Inc..
In the past 12 months, Canaccord Genuity or its affiliated companies have received compensation for Investment Banking services from
Aurora Cannabis Inc. .
In the past 12 months, Canaccord Genuity or any of its affiliated companies have been lead manager, co-lead manager or co-manager of
a public offering of securities of Aurora Cannabis Inc. or any publicly disclosed offer of securities of Aurora Cannabis Inc. or in any related
derivatives.
Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking
services from Aurora Cannabis Inc. in the next three months.
For the purposes of UK regulation, as of the month end immediately preceding the date of publication of this research, on the date of
publication of this research, or the prior month end if publication of this research is within 10 days following a month end, Canaccord
Genuity or its affiliated companies, in the aggregate, beneficially owned 0.5% or more of any class of the total issued share capital or
other common equity securities of Aurora Cannabis Inc. or held any other financial interests in Aurora Cannabis Inc. which are significant
in relation to the research (as disclosed below).
An analyst has visited the material operations of Aurora Cannabis Inc.. No payment was received for the related travel costs.
Aurora Cannabis Inc. Rating History as of 06/28/2017
I:SB:C$2.75 SB:C$3.15 SB:C$3.25
11/02/16 12/14/16 05/03/17
C$3.50
C$3.00
C$2.50
C$2.00
C$1.50
C$1.00
C$0.50
C$0.00
Jul 14 Oct 14 Jan 15 Apr 15 Jul 15 Oct 15 Jan 16 Apr 16 Jul 16 Oct 16 Jan 17 Apr 17

Closing Price Target Price

Buy (B); Speculative Buy (SB); Sell (S); Hold (H); Suspended (SU); Under Review (UR); Restricted (RE); Not Rated (NR)

Online Disclosures
Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically)
http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn:
Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request
by email to disclosures@canaccordgenuity.com. The reader may also obtain a copy of Canaccord Genuitys policies and procedures
regarding the dissemination of research by following the steps outlined above.
General Disclaimers
See Required Company-Specific Disclosures above for any of the following disclosures required as to companies referred to in this
report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research
analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related
derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in
a hyperlink located in the section labeled, Compendium Reports. Canaccord Genuity is the business name used by certain wholly
owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity Inc., Canaccord Genuity Limited, Canaccord Genuity
Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 50%-owned by Canaccord Genuity Group Inc.
The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian
broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity Inc., a US broker-dealer
with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with

Speculative Buy unchanged Target Price C$3.25 unchanged | 29 June 2017 Canadian Cannabis 4
 Aurora Cannabis Inc.
Company Update

principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with
principal offices located in Sydney and Melbourne.
The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon
(among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts
have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking
activities, or to recommendations contained in the research.
Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as
a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuitys policy on
managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuitys policy is
available upon request.
The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the
exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity,
its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not
independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained
in this research constitute Canaccord Genuitys judgement as of the date of this research, are subject to change without notice and are
provided in good faith but without legal responsibility or liability.
From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or
trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this
research. Canaccord Genuitys affiliates, principal trading desk, and investing businesses also from time to time make investment
decisions that are inconsistent with the recommendations or views expressed in this research.
This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated
investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated
investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no
circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company
that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for
general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any
particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision.
To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability
whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.
Research Distribution Policy
Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all
of Canaccord Genuitys customers who are entitled to receive the firm's research. In addition research may be distributed by the firms
sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also
receive it via third party vendors. Until such time as research is made available to Canaccord Genuitys customers as described above,
Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior
compliance consent.
For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should
contact their local sales representative.
Short-Term Trade Ideas
Research Analysts may, from time to time, discuss short-term trade ideas in research reports. A short-term trade idea offers a near-
term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may
be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A
short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research
analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons,
methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-
term Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other
reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or Speculative Buy could be
considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over
the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not
undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are
not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding
any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuitys
research.
For Canadian Residents:
This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination
in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC)
and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment
discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

Speculative Buy unchanged Target Price C$3.25 unchanged | 29 June 2017 Canadian Cannabis 5
 Aurora Cannabis Inc.
Company Update

For United States Persons:

Canaccord Genuity Inc., a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States.
This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect
transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Inc. Analysts
employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These
analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the FINRA Rule 2241 and NYSE
Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst
account.
For United Kingdom and European Residents:
This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited,
which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible
Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and
Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being
distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net
Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for
distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority.
For Jersey, Guernsey and Isle of Man Residents:
This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be
construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced
by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are
providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client
agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any
doubt, you should consult your financial adviser.
CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle
of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group
Inc.
For Australian Residents:
This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No
234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account
their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial
products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited. Canaccord
Genuity Wealth Management is a division of Canaccord Genuity (Australia) Limited.
For Hong Kong Residents:
This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures
Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities
and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of
this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or
in connection with, this research.
Additional information is available on request.
Copyright Canaccord Genuity Corp. 2017 Member IIROC/Canadian Investor Protection Fund
Copyright Canaccord Genuity Limited. 2017 Member LSE, authorized and regulated by the Financial Conduct Authority.
Copyright Canaccord Genuity Inc. 2017 Member FINRA/SIPC
Copyright Canaccord Genuity (Australia) Limited. 2017 Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and
regulated by ASIC.
All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord
Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity Inc or Canaccord Genuity Group Inc. None of the material, nor its content,
nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written
permission of the entities listed above.
None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party
including by way of any form of social media, without the prior express written permission of the entities listed above.

Speculative Buy unchanged Target Price C$3.25 unchanged | 29 June 2017 Canadian Cannabis 6